Sudeep Pharma Q4 FY26: Growth Holds Up as the Company Funds Its Next Phase

Sudeep Pharma Limited closed Q4 FY26 with steady growth despite a volatile cost and supply backdrop. Consolidated revenue from operations rose to Rs 182.3 crore, up 16 percent year on year. Profitability expanded in absolute terms, though margins softened. EBITDA was Rs 62.6 crore, up 6 percent, while PAT came in at Rs 48.5 crore, up 10 percent.

For the full year, FY26 was a step-change. Revenue reached Rs 642.3 crore, up 28 percent, which management described as the company’s highest ever. EBITDA grew 17 percent to Rs 221.9 crore and PAT rose 26 percent to Rs 174.3 crore. The year also included a structural milestone: the listing of Sudeep Pharma Limited, which management positioned as a stronger platform for long-term growth.

The Managing Director, Mr. Sujit Bhayani, framed FY26 as a year of execution on multiple tracks: integrating the newly acquired Nutrition Supplies Services business through the company’s subsidiary, advancing a greenfield expansion at Nandesari, and starting to build a new battery materials franchise around battery-grade iron phosphate. The quarter also carried temporary disruptions from gas supply issues, sharp increases in sulphuric and phosphoric acid prices, and supply chain challenges linked to the West Asia conflict. Yet the company maintained growth and highlighted customer price revisions that should flow through progressively.

Q4 and FY26 results: growth with margin pressure

The headline numbers show a business scaling fast, but also absorbing new operating realities. In Q4 FY26, EBITDA margin was 34.3 percent versus 37.3 percent in Q4 FY25. For FY26, EBITDA margin was 34.6 percent versus 37.8 percent in FY25. PAT margin was comparatively resilient at 26.6 percent in Q4 and 27.1 percent for the year.

A key part of the FY26 story is mix. In Q4 FY26, the company’s revenue split shifted to 51 percent Specialty Ingredients and 49 percent Pharma and Food Nutrition, compared with 71 percent Pharma and Food Nutrition in Q4 FY25. For the full year, Specialty Ingredients rose to 44 percent of revenue versus 34 percent in FY25. This shift matters because it signals both portfolio expansion and the early effects of the NSS acquisition, which started contributing to revenue from 22 May 2025.

Geographically, the company remained export-led. Exports were 55 percent of revenue in Q4 FY26 and 60 percent for FY26, showing that growth is not limited to the domestic market. Management also noted expanded presence in Peru and improving traction and customer engagement in the US and Europe.

The financial statements also show a noticeable increase in scale and complexity. Other income rose sharply in FY26 to Rs 28.6 crore from Rs 9.3 crore in FY25. Depreciation increased to Rs 14.8 crore from Rs 10.6 crore, consistent with ongoing investments and additions.

Portfolio shift and execution: NSS integration and regulated-market reach

Management highlighted the acquisition of an 85 percent stake in Nutrition Supplies Services through its wholly owned subsidiary, Sudeep Pharma B.V., as a strategic strengthening of advanced formulation capabilities. NSS operates in vitamin and mineral blends, with tailored premix products across dry blends, water soluble blends, oil soluble blends, and blends for high care infant nutrition and critical care segments. The company also emphasized that NSS provides a domestic manufacturing facility in Europe and several customer approvals and novel formulations.

Operationally, the company has appointed a new business head for NSS and described the integration as progressing smoothly, with encouraging operational and customer synergies. There is a nuance in the numbers that investors should track: working capital days expanded, in part because NSS inventory has been consolidated while sales contribution reflects nearly 10 months. That suggests the P and L has started to benefit from NSS, but the balance sheet is still absorbing the setup and integration.

The longer-term strategic logic is clear in the company’s own narrative. Sudeep Pharma has gradually moved from being primarily a pharma excipients manufacturer to a technology-led specialty ingredients business with capabilities such as encapsulation, spray drying, granulation, blending, liposomal preparation, and trituration. The investor presentation positions proprietary technologies as a core differentiator and references regulatory certified infrastructure with a broad set of facility and product certifications.

In a quarter where raw material inflation in phosphoric acid and sulphuric acid was pronounced, the company’s ability to pass on price revisions becomes a practical test of customer stickiness. Management stated that it was largely able to pass through these increases, helping mitigate margin impact. If those revisions fully reflect in coming quarters, it may also provide a clearer view of underlying profitability once the temporary disruptions fade.

Investment cycle: greenfield expansion and the working capital build

While earnings grew strongly, FY26 also shows an investment-led compression in return ratios. ROCE fell to 22.52 percent in FY26 from 30.03 percent in FY25, and ROE declined to 19.41 percent from 28.13 percent. The company attributes this compression primarily to ongoing investments in the greenfield project at Nandesari, the NSS acquisition, and IPO proceeds that are yet to be deployed.

Working capital is another pressure point. Net working capital days climbed to 213 in FY26 from 184 in FY25, and from 128 in FY24. The company provided a clear set of drivers: newly established warehousing operations in the US and Europe with inventory turnover expected to begin over the next few quarters, NSS inventory consolidation versus partial-year sales, and extended lead times due to the West Asia conflict.

The balance sheet reflects the same story. Total assets rose to Rs 1,174.9 crore at March 2026 from Rs 717.2 crore at March 2025. Non-current assets increased to Rs 550.9 crore, including capital work-in-progress of Rs 178.4 crore and goodwill of Rs 68.2 crore. Inventories rose to Rs 216.0 crore from Rs 128.7 crore and receivables increased to Rs 227.5 crore from Rs 185.4 crore.

Cash flow reveals how the investment cycle is being funded. Operating cash flow improved to Rs 69.5 crore in FY26 from Rs 48.7 crore in FY25, but investing cash flow was a large outflow of Rs 330.9 crore. Financing cash flow was an inflow of Rs 247.3 crore, consistent with the company raising capital and using debt to support expansion and acquisitions.

The company’s utilization of IPO net proceeds shows that a major portion remains to be deployed. Of the Rs 88.3 crore original amount, Rs 12.5 crore was utilized in FY26 for general corporate purposes, with Rs 75.8 crore unutilized for capital expenditure towards procurement of machinery for the production line at Nandesari Facility I. This is an important bridge between today’s earnings and tomorrow’s capacity, and it also explains part of the return ratio compression.

Battery materials: building a non-China supply alternative

The most forward-looking part of the presentation is the battery materials plan under Sudeep Advanced Materials, focused on battery-grade iron phosphate for LFP batteries. The company held a groundbreaking ceremony for its battery materials plant at Dahej, Gujarat, with a project cost of approximately Rs 300 crores and targeted completion by early CY27. Financing is planned through internal accruals and debt. The plant’s Phase 1 capacity is planned at 25,000 MT, with a longer-term target of 100,000 MT by 2030.

Management’s commentary suggests early commercial validation. During the quarter, the company received qualification orders from Korean customers and a 500 MT purchase order from a leading listed player in India. The presentation also references secured commercial purchase orders of 700 MT volume in recent months. The company states it has upgraded existing pharma iron phosphate capacity to produce 5,000 MT of battery-grade material.

Strategically, the company positions itself as an emerging reliable non-Chinese supplier for battery-grade iron phosphate precursor. It also frames this as aligned with FEOC compliance norms and customer regulations under the US IRA and EU Critical Raw Materials Act. While these claims need to be tracked through customer wins and steady shipments, the framing is important: the company is tying a chemistry capability it already has into a fast-growing global end market.

The capacity roadmap ties all growth levers together. Pharma, Food and Nutrition capacity is shown at 35,000 MT existing, with a jump to 86,200 MT in FY27e driven by the greenfield project addition of 51,200 MT. Specialty Ingredients capacity increases from 30,000 MT in FY25 to 37,500 MT, with NSS adding 7,500 MT in FY26. Battery materials capacity begins at 25,000 MT in FY27e and steps up to 100,000 MT by FY30e.

Investor takeaways: strong FY26, but watch cash and execution

Sudeep Pharma’s Q4 FY26 results show a company that is growing through mix shift, expansion, and acquisitions, while navigating temporary disruptions and input cost spikes. The year delivered strong top-line growth and healthy absolute profit growth. But it also pulled forward balance sheet intensity, with higher working capital days, larger capital work-in-progress, and compressed ROCE and ROE.

The central theme for investors is disciplined execution through an investment cycle. The NSS integration needs to convert into sustained revenue and normalized working capital as warehousing and inventory turnover stabilizes. The Nandesari greenfield project needs to move from internal validation to customer validation and then qualification, which the company notes can take 6 to 12 months. And the Dahej battery materials facility needs to translate early traction into repeat orders as Phase 1 comes closer to commissioning in early CY27.

If these pieces come together, FY26 could be remembered as the year Sudeep Pharma built the platform, not just the earnings. The next few quarters should show whether pricing actions, improved logistics, and execution on capacity additions can bring margins and returns closer to historical levels while sustaining growth in exports and specialty ingredients.